Better Health for All

Synlogic's core business is dedicated to developing Synthetic Biotic medicines for rare metabolic and inflammatory diseases, including Phenylketonuria (PKU), Homocystinuria (HCU), and Inflammatory Bowel Disease (IBD), aiming to provide new treatment options for patients with limited alternatives.

This focus on serious conditions with unmet needs aligns with a strong positive health impact. The company has received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) for several programs, indicating a focus on vulnerable populations, including children and those with rare diseases. While the Synpheny-3 study for PKU was discontinued due to unlikelihood of meeting its primary endpoint, the treatment was found to be safe and well-tolerated. Synlogic's pre-approval access policy requires informed consent and a review of potential benefits versus risks, but also allows for discontinuation at the company's discretion. The company received a U.S. patent extending exclusivity to 2041 for one of its treatments, and ODD grants seven years of market exclusivity after approval. , Synlogic closed a $21.0 million public offering and earned a $2.5 million milestone payment from Roche, but no percentage of R&D budget allocated to health improvement is provided. The company conducts randomized, placebo-controlled, global, pivotal Phase 3 clinical trials, with study information available on clinicaltrials.gov, and requires FDA/IRB/IEC approval for pre-approval access. , Synlogic's Synpheny-3 study is a global study, but no further details on health equity programs are provided. The company will reduce its workforce by more than 90% in February 2024.

Fair Money & Economic Opportunity

Synlogic, Inc. is a biotechnology company focused on drug discovery and development, not a financial institution. As such, it does not offer lending, deposit, or other financial services to consumers.

Therefore, all KPIs related to financial products, customer segments, pricing, fees, lending practices, wealth building outcomes for customers, or financial literacy initiatives for the public are not applicable to its core business model. The company's internal employee benefits, such as a 401(k) match and an Employee Stock Purchase Plan, relate to employee wealth building, not customer outcomes. Similarly, its general corporate governance disclosures and internal DEI initiatives do not pertain to financial inclusion for underserved populations through financial products.

Fair Trade & Ethical Sourcing

No information relevant to Fair Trade & Ethical Sourcing for SYBX.US was found in the provided articles. All articles either explicitly stated no relevant data was present

or indicated a 'Page Not Found' error , meaning no specific, concrete data points could be extracted for any KPI.

Honest & Fair Business

No specific, quantitative data points were found in the provided articles to assess Synlogic, Inc. against any of the 'Honest & Fair Business' KPIs.

explicitly states a lack of quantitative data or specific metrics, and indicates insufficient data due to retrieval issues.

Kind to Animals

Synlogic conducts preclinical studies using animal models, including mice and non-human primates, for its SYNB1618, SYNB1934, SYNB1020, and SYNB1353 programs. There is no evidence that the company employs non-animal testing methods for product safety and efficacy. For SYNB1934, twelve male cynomolgus monkeys were used.

The company's animal testing policy involves compliance with the Animal Welfare Act regulations, Public Health Service Policy, and the Guide for the Care and Use of Laboratory Animals, with procedures approved by Institutional Animal Care and Use Committees (IACUCs) at Synlogic and Charles River Laboratories. Animals in NHP studies were socially housed with environmental enrichment. The company's R&D budget allocation to animal-free technologies is not specified, but increasing investments in regenerative medicine and pharmaceutical R&D are noted to indirectly support alternative testing methods. There is no evidence of Synlogic's participation in multi-stakeholder initiatives for animal-free testing standards or active engagement in animal welfare policy improvement.

No War, No Weapons

The provided articles for Synlogic, Inc. (SYBX.US) explicitly state that they do not contain any specific, concrete data points or information relevant to any of the Key Performance Indicators for the 'No War, No Weapons' ethical value.

Therefore, all KPIs are omitted due to lack of evidence.

Planet-Friendly Business

Synlogic requires all employees, officers, and directors to comply with applicable environmental laws and regulations.

Employees are responsible for promptly reporting any environmental law violations, and the company prohibits retaliation for such reports unless knowingly false. Synlogic leases its office and manufacturing facilities and recognizes the importance of reducing its environmental footprint, committing to reduce, reuse, or recycle where possible. No specific quantitative data or outcomes regarding environmental performance, emissions, targets, or certifications were provided.

Respect for Cultures & Communities

The company has no reported cultural appropriation incidents attributed to its operations.

Its business model, focused on biotechnology R&D, does not inherently involve cultural contexts that would typically require Free, Prior, and Informed Consent (FPIC) processes, specific cultural impact assessments, or cultural site protection. While the company has internal grievance mechanisms for employees regarding accounting, auditing, and ethics, there is no evidence of specific grievance mechanisms available for community concerns. Similarly, there is no evidence of community representation in governance bodies, or a formal framework for responding to cultural incidents. The company partners with Life Science Cares and other organizations for internship opportunities and engages in philanthropic endeavors, but no specific numbers or percentages are provided for these activities, nor for local employment, procurement, or cultural preservation investments.

Safe & Smart Tech

Synlogic's website uses secure software encryption (SSL) to protect personal information such as credit card data, name, and address before transmission, which represents standard industry practice.

The company provides individuals with opportunities to review and change collected personal information, and users are entitled to access, delete, correct, object to processing, request restriction of processing, or revoke consent for their personal data, demonstrating excellent privacy controls. Synlogic integrates privacy principles into its development lifecycle by considering the amount, nature, and sensitivity of personal data, potential risks, processing purposes, and alternative means, indicating privacy as a development priority. The company also demonstrates very good data minimization practices by retaining personal information only as long as necessary to fulfill collected purposes and by considering the amount, nature, and sensitivity of data. Synlogic is subject to and complies with various U.S. federal and state, and foreign laws and regulations, including SEC rules, and has procedures to notify regulators of suspected data breaches where legally required. The company has agreements in place with employees and service providers to keep personal data confidential and not use it for unauthorized reasons, which aligns with standard data governance practices.

Zero Waste & Sustainable Products

Synlogic, Inc. and its third-party manufacturers and suppliers engage in the controlled storage, use, and disposal of hazardous materials as part of their research and development activities, adhering to applicable laws and regulations.

No specific information is available regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.